Progesterone Receptor-negative Breast Cancer Active Not Recruiting Phase 2 Trials for Eribulin (DB08871)

IndicationStatusPhase
DBCOND0028547 (Progesterone Receptor-negative Breast Cancer)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01372579Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer PatientsTreatment